Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

Fig. 4

Flow cytometry analysis of peripheral blood T cells before (a) and after treatment (b). The expression of the immune markers (from left to right) TIM-3, Lag-3, and PD-1, on CD3+ T cells counter-stained for CD8 were analyzed. c Immunostaining of tumor cells following radiotherapy for PD-L1. d Real-time quantitative RT-PCR analysis of baseline and post radiotherapy tumor biopsy specimens for the content of mRNAs specific for the T cell markers CD4, CD8, the checkpoint inhibitor PD-L1, the pro-inflammatory cytokine TNFα, and the macrophage marker CD11b. ND none detected. The quantitative RT-PCR assay uses artificial gene standards for positive controls and is sensitive to the level of 10 copies per sample

Back to article page